16
Views
1
CrossRef citations to date
0
Altmetric
ANATOMICAL PATHOLOGY

BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas

, , , &
Pages 201-204 | Received 15 Nov 2005, Accepted 07 Feb 2006, Published online: 06 Jul 2009

References

  • Davies H., Bignell G. R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949–54
  • Kimura E. T., Nikiforova M. N., Zhu Z., Knauf J. A., Nikiforov Y. E., Fagin J. A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC‐RAS‐BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63: 1454–7
  • Cohen Y., Xing M., Mambo E., et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003; 95: 625–7
  • Soares P., Trovisco V., Rocha A. S., et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003; 22: 4578–80
  • Xu X., Quiros R. M., Gattuso P., Ain K. B., Prinz R. A. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003; 63: 4561–7
  • Namba H., Nakashima M., Hayashi T., et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003; 88: 4393–7
  • Fukushima T., Suzuki S., Mashiko M., et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 2003; 22: 6455–7
  • Nikiforova M. N., Kimura E. T., Gandhi M., et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. Clin Endocrinol Metab 2003; 88: 5399–404
  • Xing M., Vasko V., Tallini G., et al. BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab 2004; 89: 1365–8
  • Kim K. H., Kang D. W., Kim S. H., Seong I. O., Kang D. Y. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004; 45: 818–21
  • Puxeddu E., Moretti S., Elisei R., et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 2004; 89: 2414–20
  • Fugazzola L., Mannavola D., Cirello V., et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 2004; 61: 239–43
  • Ciampi R., Knauf J. A., Kerler R., et al. Oncogenic AKAP9‐BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 2005; 115: 94–101
  • Peyssonnaux C., Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001; 93: 53–62
  • Avruch J., Khokhlatchev A., Kyriakis J. M., et al. Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res 2001; 56: 127–55
  • Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000; 351: 289–305
  • Mercer K. E., Pritchard C. A. Raf proteins and cancer: B‐Raf is identified as a mutational target. Biochim Biophys Acta 2003; 1653: 25–40
  • Sithanandam G., Druck T., Cannizzaro L. A., Leuzzi G., Huebner K., Rapp U. R. B‐raf and a B‐raf pseudogene are located on 7q in man. Oncogene 1992; 7: 795–99
  • Edwards A. S., Scott J. D. A‐kinase anchoring proteins: protein kinase A and beyond. Curr Opin Cell Biol 2000; 12: 217–21
  • Witczak O., Skalhegg B. S., Keryer G., et al. Cloning and characterization of a cDNA encoding an A‐kinase anchoring protein located in the centrosome, AKAP450. EMBO J 1999; 18: 1858–68
  • Takahashi M., Shibata H., Shimakawa M., Miyamoto M., Mukai H., Ono Y. Characterization of a novel giant scaffolding protein, CG‐NAP, that anchors multiple signaling enzymes to centrosome and the golgi apparatus. J Biol Chem 1999; 274: 17267–74
  • Schmidt P. H., Dransfield D. T., Claudio J. O., et al. AKAP350, a multiply spliced protein kinase A‐anchoring protein associated with centrosomes. J Biol Chem 1999; 274: 3055–66

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.